# Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer

> **NCT00003066** · PHASE2 · UNKNOWN · sponsor: **Herbert Irving Comprehensive Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** docetaxel
- **DRUG:** estramustine phosphate sodium

## Key facts

- **NCT ID:** NCT00003066
- **Lead sponsor:** Herbert Irving Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003066, "Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00003066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*